Ramping up for sure.
They stalled the run when they first announced the merger, then silently listed their failed FDA trial in that q. They have more stuff in the pipeline and once the merger is done, maybe they can ramp revenue.
Where is the bottom to XERS? I grabbed a a couple hundred a few days ago and it just keeps dropping more an more. Even after the good news today and yesterday. I was hoping maybe someone had an opinion they would like to share. Also does anyone know the real OS or Float? When I look at the OTC website I see it hasn't been updated since March 22nd.
Thanks for any feed back. Much appreciated
Ownership of 5 Percent or Less of a Class. If this statement is being
filed to report the fact that as of the date hereof the reporting person
has ceased to be the beneficial owner of more than 5 percent of the
class of securities, check the following [ X ].
Blackrock sold 2.1m shares into it since their last filing in May until today. If they are done suppressing it now, maybe it can finally head north to where it belongs.
Nom nom nom bring the gains.
They are acquiring another company, which pushed the profitability timeline back and it reflected in that. That said, it'll cross the threshold a little harder. Some nice gains whether flipping or bottom feeding long.
Recent announcement of deal caused PT to go from $14 to $9.
Once these conversions clear the landscape will probably change quick. I would think we are close too, but...
Good news out after hours. $$$
Wonder if the convertible debt is done now. Looking like it may be. Gonna get interesting when it dries up.
Made some big buys over the last few days and all of them bared fruit today. Here's to the green mile.
My thoughts exactly. Hopefully the dance continues for this and many other stocks.
Almost all of the convertible debt is extinguished. At current rate, probably in the next 10 days it will be gone at an average of $3ish a share, hence this hard drop. They have growing revenue, could be building the perfect storm. They have plenty of cash on hand. Started buying at $4.50 and have buys down to $3. Any takes on it?
$XERS | #Xeris Pharma On Breakout Watch
Alert set for a break above the 200ma and $5.00 level.
Highly speculative with high Risk| Reward .
Xeris Pharmaceuticals , Inc.is a pharmaceutical company, which develops and commercializes ready-to-use, liquid-stable injectables. It offers XeriSol and XeriJect formulation technologies. Its products include Gvoke Pre-Filled Syringe and Gvoke HypoPen. The company was founded by Steven Prestrelski and John Kinzell in 2005 and is headquartered in Chicago, IL.
PLEASE GIVE US A LIKE IF YOU FIND OUR CONTENT HELPFUL, THANK YOU.
Do you think we are ready here crude? $XERS
On June 30, 2020, Xeris Pharmaceuticals, Inc. (the “Company”) completed its previously announced underwritten public offering (the “Notes Offering”) of $75.0 million aggregate principal amount of the Company’s 5.00% Convertible Senior Notes due 2025 (the “Notes”). As previously announced, the Company granted the underwriters of the Notes Offering a 30-day option to purchase up to an additional $11.25 million aggregate principal amount of Notes, solely to cover over-allotments. As of the date of this Current Report on Form 8-K, the underwriters of the Notes Offering have not exercised their option to purchase additional Notes.
Xeris Pharmaceuticals (NASDAQ:XERS) Cut to "Hold" at Zacks Investment Research
6/23/20, 03:32 AM - Ticker Report
Zacks Investment Research lowered shares of Xeris Pharmaceuticals (NASDAQ:XERS) from a buy rating to a hold rating in a research report released on Saturday morning, Zacks.com reports. Zacks Investment Research currently has $5.75 target price on the stock. According to Zacks, Xeris ...